Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels

被引:20
|
作者
Xu, Jie [1 ,2 ,3 ]
Hao, Xiwa [1 ,2 ,3 ,6 ]
Zhan, Rui [2 ,3 ,4 ,5 ]
Jiang, Xue [2 ,3 ,4 ,5 ]
Jin, Aoming [1 ,2 ,3 ]
Xue, Jing [2 ,3 ,4 ,5 ]
Cheng, Aichun [1 ,2 ,3 ]
Liu, Jiewen [1 ,2 ,3 ]
Lin, Jinxi [7 ]
Meng, Xia [1 ,2 ,3 ]
Li, Hao [1 ,2 ,3 ]
Zheng, Lemin [2 ,3 ,4 ,5 ]
Wang, Yongjun [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[2] Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[3] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Minist Educ, Inst Cardiovasc Sci, Beijing, Peoples R China
[5] Peking Univ, Hlth Sci Ctr, Inst Syst Biomed, Sch Basic Med Sci,Key Lab Mol Cardiovasc Sci,Mini, Beijing, Peoples R China
[6] Baotou Cent Hosp, Dept Neurol, Baotou, Inner Mongolia, Peoples R China
[7] McGill Univ, Montreal, PQ, Canada
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
apolipoprotein; cardiovascular disease; inflammation; ischemic stroke; phospholipid; ACUTE ISCHEMIC-STROKE; CARDIOVASCULAR RISK; DISEASE; EVENTS;
D O I
10.1161/STROKEAHA.121.034924
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Lp(a) (lipoprotein(a)) contributes to cardiovascular disease mainly through proatherogenic and proinflammatory effects. Here, we aimed to evaluate whether a residual stroke risk of Lp(a) would remain when the LDL-C (low-density lipoprotein cholesterol) and inflammatory levels are maintained low. Methods: This prospective cohort study included 9899 patients with ischemic stroke or transient ischemic attack from the Third China National Stroke Registry who had measurements of plasma Lp(a) and were followed up for 1 year. Cutoffs were set at the 50 mg/dL for Lp(a). LDL-C was corrected for Lp(a)-derived cholesterol (LDL-Cc [LDL-C corrected]) and cutoffs were set at 55 and 70 mg/dL.The threshold values of IL-6 (interleukin 6) and hsCRP (high-sensitive C-reactive protein) were the median 2.65 ng/L and 2 mg/L. Multivariable-adjusted hazard ratio (HR) were calculated using Cox regression models for each category to investigate the associations of Lp(a) with stroke recurrence within 1 year. Results: Among all patients, those with Lp(a) >= 50 mg/dL were at higher stroke recurrence risk than those with Lp(a) <50 mg/dL (11.5% versus 9.4%; adjusted HR, 1.20 [95% CI, 1.02-1.42]). However, the risk associated with elevated Lp(a) was attenuated in patients with LDL-Cc <55 mg/dL (high Lp(a) versus low Lp(a): 8.9% versus 9.0%; adjusted HR, 0.92 [95% CI, 0.65-1.30]) or IL-6 <2.65 ng/L (9.0% versus 7.8%; adjusted HR, 1.14 [95% CI, 0.87-1.49]). Notably, in the group with both low LDL-Cc and inflammation levels, the rate of patients with high Lp(a) did not significantly different from the rate of patients with low Lp(a; LDL-Cc <55 mg/dL and IL-6 <2.65 ng/L: 6.2% versus 7.1%; adjusted HR, 0.86 [95% CI, 0.46-1.62]; LDL-Cc <55 mg/dL and hsCRP <2 mg/L: 7.7% versus 7.6%; adjusted HR, 0.97 [95% CI, 0.57-1.66]). However, there was no interaction between the LDL-Cc, IL-6, hsCRP, and Lp(a) levels on stroke recurrence risk. Conclusions: Increased Lp(a) was significantly associated with stroke recurrence risk in patients with ischemic stroke/transient ischemic attack. However, at low LDL-Cc or IL-6 levels, the elevated Lp(a) -associated stroke recurrence risk was attenuated in a secondary prevention setting.
引用
收藏
页码:2504 / 2511
页数:8
相关论文
共 50 条
  • [1] Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
    Whayne, Thomas F., Jr.
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (04) : 374 - 379
  • [2] The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels br
    Zhang, Xing
    Lv, Wei
    Xu, Jie
    Li, Jiejie
    Pan, Yuesong
    Yan, Hongyi
    Li, Hao
    Li, Zixiao
    Meng, Xia
    Wang, Yongjun
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (11) : 1634 - 1645
  • [3] EVOLOCUMAB-INDUCED PARADOXICAL RISE OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS
    Yee, Brianna
    Dugal, Jasmine
    Dicaro, Michael
    Lee, Ki
    Malhotra, Sanjay
    Ahsan, Chowdhury H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2855 - 2855
  • [4] LOW-DENSITY LIPOPROTEIN (LDL) RECEPTORS AND THE REGULATION OF SERUM LDL LEVELS
    VERMEER, BJ
    NETHERLANDS JOURNAL OF MEDICINE, 1985, 28 (02): : 52 - 58
  • [5] Effect of clinical pharmacist intervention on low-density lipoprotein cholesterol (LDL-C) outcomes in an ambulatory setting
    Guy-Alfandary, S
    Lavi, S
    Raz, M
    Triki, N
    VALUE IN HEALTH, 2005, 8 (03) : 271 - 271
  • [6] Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis
    Dixon, Dave L.
    Khaddage, Sarah
    Bhagat, Shailja
    Koenig, Rachel A.
    Salgado, Teresa M.
    Baker, William L.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (03) : 282 - +
  • [7] Time for new low density lipoprotein cholesterol (LDL-C) targets?
    Daskalopoulou, Stella S.
    Mikhailidis, Dimitri P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1539 - 1541
  • [8] Elevated low-density lipoprotein cholesterol (LDL-C) enhances proerectile neurotransmission in the corpus cavernosum
    B Srilatha
    PG Adaikan
    SC Ng
    S Arulkumaran
    International Journal of Impotence Research, 1999, 11 : 159 - 165
  • [9] Elevated low-density lipoprotein cholesterol (LDL-C) enhances proerectile neurotransmission in the corpus cavernosum
    Srilatha, B
    Adaikan, PG
    Ng, SC
    Arulkumaran, S
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 1999, 11 (03) : 159 - 165
  • [10] Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients
    Bairaktari, E
    Elisaf, M
    Tzallas, C
    Karabina, SA
    Tselepis, AD
    Siamopoulos, KC
    Tsolas, O
    CLINICAL BIOCHEMISTRY, 2001, 34 (08) : 593 - 602